Hansa Biopharma AB (publ)
Hansa Biopharma AB (publ)
Your view on HNSBF
Overview
What the company does, where it operates, and who runs it.
About Hansa Biopharma AB (publ)
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Renee Aguiar-Lucander
- Headquarters
- PO Box 785, Lund, SE
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Renee Aguiar-Lucander
- Headquarters
- PO Box 785, Lund, SE
Hansa Biopharma AB (publ), a biopharmaceutical company, develops immunomodulatory treatments for enabling transplants and rare immunoglobulin G (IgG)-mediated autoimmune conditions, gene therapy, and cancer using its proprietary enzyme technology platform.
The company's lead drug candidate is Imlifidase, an antibody cleaving enzyme therapy that is in phase 3 clinical trial for use in sensitized kidney transplantations patients, as well as for anti-GBM antibody disease; and phase 2 clinical trial for antibody-mediated kidney transplant rejection and Guillain Barré syndrome.
It is also developing Novel immunoglobulin cleaving enzymes for Repeat dosing (NiceR) for the treatment of autoimmune diseases, transplantation, and oncology; and Enzyme based antibody Enhancement (EnzE), which is cancer immunotherapy.
The company has a preclinical research collaboration agreement with argenx BV to evaluate the therapeutic potential of combining the two companies' IgG-modulating technologies. Hansa Biopharma AB (publ) was incorporated in 2007 and is headquartered in Lund, Sweden.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for Hansa Biopharma AB (publ), and the rating behind it. HNSBF last traded at $2.90; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for Hansa Biopharma AB (publ). Starting points for Hansa Biopharma AB (publ): EPS -$7.57, beta 1.84 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for Hansa Biopharma AB (publ). Hansa Biopharma AB (publ) does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for Hansa Biopharma AB (publ). Trailing twelve-month EPS for Hansa Biopharma AB (publ) stands at -$7.57. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for Hansa Biopharma AB (publ). Hansa Biopharma AB (publ) has reported as a listed company since 2015. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Hansa Biopharma AB (publ) valued side by side against its closest peers. Hansa Biopharma AB (publ) is measured against Biotechnology peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold Hansa Biopharma AB (publ), and how their positions are changing. At a $245.8M market value, institutional positions materially move Hansa Biopharma AB (publ)'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by Hansa Biopharma AB (publ) executives and directors. Shares of Hansa Biopharma AB (publ) have traded between $2.73 and $4.58 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming Hansa Biopharma AB (publ). Hansa Biopharma AB (publ) is a $245.8M Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming Hansa Biopharma AB (publ). Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for Hansa Biopharma AB (publ). Coverage tracks Hansa Biopharma AB (publ) within Biotechnology (Healthcare). Press releases and market coverage, newest first.